This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Ketorolac (an intravenous NSAID, in one of two doses or placebo) is given to infants admitted following surgery, following approval of the primary surgeon to determine the pharmacokinetics (PK, or drug handling), safety and pain relief. Blood samples are drawn from in-dwelling catheters placed during surgery over a 12 hour period to determine PK. Pain scores and morphine usage are compared in the drug and placebo groups. Oximetry, stool heme-occult testing, urinalysis, and renal and liver function testing constitute safety assessments. Non-premature infants aged birth to 18 months with normal renal, hepatic and hemostatic function are the eligible population.
Showing the most recent 10 out of 563 publications